Dennis Klinman, MD, PhD is trained in rheumatology and spent 18 years at the FDA, primarily in the area of viral products, with increasing levels of leadership and responsibility. He holds several score patents in the field of TLR agonists, as well as for adjuvants such as those used in Heplisav (Hepatitis B vaccine) and the newest generation anthrax vaccine. His areas of expertise include immunotherapy, cancer vaccines, innate immunity, TLR agonists, autoimmunity and regulatory affairs.
Emeritus Investigator, National Cancer Institute
Former Chief of Immune Modulation Section and Laboratory of Experimental Immunology, NCI
Former Chief of Retroviral Immunology Section and Division of Viral Products, CBER/FDA